Back to top

Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price Target

Climb Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG maintained a Buy rati...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Climb Bio, Inc. (CLYM)